An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York April 13, 2026: New video shows Mochi Health affiliated pharmacy's corner cutting Partnership for Safe Medicines BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved